Journal of Interventional Cardiac Electrophysiology最新文献

Background: Pulsed field ablation (PFA) and high-power short-duration radiofrequency ablation (HPSD) are emerging techniques for treating atrial fibrillation (AF), offering promising results compared to cryoballoon ablation (CBA). This network meta-analysis aims to evaluates the efficacy and safety of PFA, HPSD, and CBA.

Method: PubMed, Scopus and Cochrane Central Register of Controlled Trials were systematically searched for relevant studies until October 2024. The primary outcome is freedom from atrial arrhythmia. A random-effects model was used for data synthesis, and P-scores were employed for outcome ranking. Point estimation (odd ratios) was calculated for comparisons.

Results: Eighteen studies were included in our network meta-analysis, involving 7,071 atrial fibrillation patients. Among them, 2,023 (29%), 3,725 (53%), and 1,323 (18%) patients underwent PFA, CBA, and HPSD, respectively. PFA demonstrated a higher freedom from atrial arrhythmia, with an odds ratio (OR) of 3.63 (95% CI: 2.95-4.46) compared to CBA and 1.89 (95% CI: 1.47-2.43) compared to HPSD. However, PFA was associated with a higher risk of complications (OR = 6.54, 95% CI: 2.13-20.00) compared to CBA, while HPSD showed an insignificant association with a lower risk of complications compared to CBA (OR = 0.61, 95% CI: 0.15-2.42). PFA had the shortest procedural time (P-score: 100%), while HPSD had the longest (P-score: 0%). In contrast, HPSD had the shortest fluoroscopic time, with P-scores of 100%, 46%, and 3% for HPSD, PFA, and CBA, respectively.

Conclusion: PFA demonstrated higher efficacy but also a higher risk of complications compared to HPSD and CBA. HPSD showed greater efficacy with comparable safety to CBA.

Background: The conventional mapping approach for the atrioventricular accessory pathway (AP) involves point-by-point mapping to identify the connection sites of the AP to the atria or ventricle and accurate interpretation of local electrograms. Omnipolar mapping technology (OMT) explains how vector and wave speed are produced by using both unipolar and bipolar signals to obtain omnipolar signals, directions, and conduction velocity. The aim of this study is to verify the effectiveness of OMT for catheter ablation of AP.

Methods: The study enrolled 68 patients who underwent catheter ablation of APs between January 2018 and December 2023, of which 35 (OMT group) underwent high-resolution omnipolar mapping and 33 underwent radiofrequency ablation (RF) with a conventional approach (conventional group). The background characteristics and procedural details of these groups were compared.

Results: All patients achieved acute success. Any arrhythmia recurrence was observed in one and three patients in the OMT and conventional groups, respectively (p = 0.0501). In the OMT group, AP elimination by the first RF applications (77.1% vs. 48.4%, p = 0.0143), the number of RF applications for eliminating AP (median [IQR]; 1.1 [1.0-3.0] vs. 4.4 [1.0-7.0], p = 0.0012), procedure time (median [IQR], min; 80.1 [72.2-92.7] vs. 112.0 [95.1-125.4], p < 0.01), fluoroscopy time (median [IQR], min; 12.0 [9.5-15.2] vs. 19.8 [13.6-28.1], p < 0.01), and fluoroscopy dose (median [IQR], mGy; 60.9 [45.0-83.5] vs. 129.0 [80.5-360.2], p < 0.01) were significantly lower than in the conventional group. No complications associated with mapping and ablation procedures were observed.

Conclusions: The OMT was useful for ablating APs and reducing the number of RF applications and radiation exposure.

Purpose: The aim of the present study was to evaluate the outcome of patients underwent subcutaneous implantable cardioverter defibrillator (S-ICD) implantation with the intermuscular (IM) two-incision technique during 3-year follow-up.

Methods: the study population consisted of 105 consecutive patients (79 male; median 50 [13-77] years) underwent S-ICD implantation with the IM two-incision technique. The composite primary end point of the study consisted of device-related complications and inappropriate shocks (IAS). Secondary end points included the individual components of the primary end point, death from any cause, appropriate therapy, major adverse cardiac events, hospitalization for heart failure, and heart transplantation.

Results: According to the PRAETORIAN score, the risk of conversion failure was classified as low in 99 patients (94.3%), intermediate in 6 (5.7%).Ventricular fibrillation was successfully converted at ≤65 J in 97.4% of patients. During a median follow-up of 39 (16-53) months, 10 patients (9.5%) experienced device-related complications, and 9 (8.5%) patients reported IAS. Lead-associated complications were the most common (5 patients, 4.7%), including 2 cases of lead failure (1.9%). Pocket complications were reported in 2 patients (1.9%). Extra-cardiac oversensing (3.8%) represented the leading cause of IAS. No T-wave oversensing episodes were recorded. Twelve patients (11.4%) experienced appropriate shocks. Eight patients (7.6%) died during follow-up. IAS or device-related complications did not impact on mortality.

Conclusions: The overall device-related complications and IAS rates over 3 years of follow-up were 9.5% and 8.5%, respectively. According to our findings, the IM two-incision technique allows for optimal positioning of the device achieving a low PRAETORIAN score with a high conversion rate. IM two-incision technique allows low incidence of pocket complications, shifting the type of complications towards lead-related complications, which represent the most common complications. The IM two-incision technique would not seem to impact the occurrence of IAS. Management of complications are safe without impact on the outcome.

Introduction: Managing atrial fibrillation in kidney transplant patients poses a challenge for both nephrologists and cardiologists. Data regarding the safety and efficacy of catheter ablation in this patient's cohort is scarce.

Methods and results: In this two-center prospective study, we included all consecutive kidney transplant patients who underwent atrial fibrillation ablation between April 2017 and March 2022. A 1:3 propensity score matching created a control group of non-transplant AF patients undergoing ablation. We included 16 kidney transplant patients and 48 matched controls. Ablation was successful in all patients. The periprocedural complication rate (6.3% in the kidney transplant group vs. 6.3% in the control group, p value = 1) did not differ between the two groups. One transplant patient experienced graft dysfunction after a complication. At 18 months, AF recurrence-fee rates were 69% in the transplant group and 70.1% in controls (p = 0.95). By the last follow-up, all transplant patients had discontinued antiarrhythmic drugs, while 19.6% of the patients in the control group were treated with antiarrhythmic drugs (p = 0.09). Kidney function in the transplant group remained stable (eGFR 32 [23.8, 40.5] ml/min/1.73 m² before vs. 34 [29.8, 38] ml/min/1.73 m² at last follow up, p = 0.93).

Conclusions: This study demonstrates that catheter ablation is a viable option for treating AF in kidney transplant patients, with comparable outcomes to non-transplanted individuals. Discontinuing antiarrhythmic drugs reduces drug interaction risks, but minimizing procedural complications remains critical to preserving graft function.

Background: Transcatheter aortic valve replacement (TAVR) is occasionally complicated by high degree atrioventricular block (AVB) requiring permanent pacemaker (PPM) placement. Newer valve design, delivery platform evolution, and deployment technique refinement have lowered this risk. Ventricular pacing ≥ 30% has been previously identified as a predictor for worse clinical outcomes in this population. This study aims to assess the prevalence of high long-term pacing burden in this cohort.

Methods: This is a retrospective study to evaluate patients from 2019 to 2023 who required PPM for high degree AVB following TAVR. Baseline demographics, clinical characteristics, procedural details were obtained. Ventricular pacing (VP) percentages were collected from PPM interrogations at 1, 6 and 12 months.

Results: 138 patients had PPM placement post-TAVR. Approximately one third of patients demonstrated ventricular pacing less than 25% at 1 month, 6 months, and 12 months (Fig. 1). Roughly 50% of patients had > 75% ventricular pacing at 1 month, 6months and 12 months. There was no difference in baseline demographics or EKG characteristics at 1 month. In a univariable logistic regression analysis, there were no statistically significant predictors of VP ≥ 30%. Although, balloon expandable valves and lower STS scores demonstrated an association with lower risk of VP ≥ 30%.

Conclusions: Our study suggests that a significant portion of patients with PPM for high degree AVB after TAVR have low pacing burden at 6-12 months. Further investigation is needed to assess valve-specific predictors and alternative pacing approaches of AVB management.